Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

mAbs

Volumn 3, Issue 1, 2011, Pages 61-66

  Deng, Rong ^a   Iyer, Suhasini ^a   Theil, Frank Peter ^a   Mortensen, Deborah L ^a   Fielder, Paul J ^a   Prabhu, Saileta ^a  

^a GENENTECH INC   (United States)

Author keywords

Allometric scaling; Clearance; Monoclonal antibody; Pharmacokinetics; Species invariant time method

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PERTUZUMAB; TRASTUZUMAB;

ALLOMETRY; ARTICLE; BODY WEIGHT; CLEARANCE; CONTROLLED STUDY; HAPLORHINI; HUMAN; NONHUMAN;

ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MICE; MODELS, BIOLOGICAL; RATS; SPECIES SPECIFICITY;

EID: 78651400009     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.1.13799     Document Type: Article

References (25)

1. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009; 157:907-21.
2. West GB, Brown JH. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 2005; 208:1575-92.
3. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15:1071-121. (Pubitemid 15158037)
4. International conference on harmonization (ICH) of technical requirments for registration of pharmaceuticals for human use: ICH Harmonized Tripartite Guideline S6 (R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 2009; www.ich.org/LOB/media/MEDIA5784.pdf.
5. Deng R, Mortensen D, Prabhu S, Jumbe N, Iyer S, Fielder P. Prediction of human pharmacokinetics for monoclonal antibody. AAPS National Biotechnology Conference, San Diego CA 2007; http://www.aapsj.org/abstracts/NBC-2007/NBC07- 000591.PDF.
6. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49:1382-402.
7. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 2010; 31:253-63.
8. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1:435-61.
9. Mahmood I. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 2009; 98:3850-61.
10. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23:2534-43.
11. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9.
12. Tang H, Mayersohn M. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 2005; 33:1288-93.
13. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26:887-95.
14. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 2004; 93:177-85. (Pubitemid 38081825)
15. Mahmood I. Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species? J Pharm Sci 2009; 98:2472-93.
16. Duconge J, Fernandez-Sanchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos 2004; 25:177-86.
17. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 2007; 24:1910-8.
18. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, et al. Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006; 148:1116-23.
19. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288:371-8.
20. Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. Preclinical pharmacokinetics, interspecies scaling and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008; 8:477-83.
21. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58.
22. Cho CY, Shin BS, Jung JH, Kim DH, Lee KC, Han SY, et al. Pharmacokinetic scaling of bisphenol A by species-invariant time methods. Xenobiotica 2002; 32:925-34.
23. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10:1093-5.
24. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633-59.
25. Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 2006; 95:1783-99. (Pubitemid 44229585)